Genotoxicity and carcinogenicity studies of antihistamines

Giovanni Brambilla1, Francesca Mattioli, Luigi Robbiano

  • 1Department of Internal Medicine, Division of Clinical Pharmacology and Toxicology, University of Genoa, Viale Benedetto XV 2, 16132 Genoa, Italy.

Archives of Toxicology
|February 18, 2011
PubMed

Insights

Many marketed antihistamines lack complete genotoxicity and carcinogenicity data. A significant portion of tested drugs showed positive results in these safety assays, highlighting potential risks.

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Safety Evaluation

Background:

  • Antihistamines are widely used medications for allergic conditions.
  • Comprehensive safety data, including genotoxicity and carcinogenicity, is crucial for marketed drugs.
  • Regulatory requirements for drug safety testing have evolved over time.

Purpose of the Study:

  • To review and compile genotoxicity and carcinogenicity assay results for marketed antihistamines.
  • To assess the completeness of safety data for these drugs based on current guidelines.
  • To identify antihistamines with positive findings in safety assays.

Main Methods:

  • Systematic review of published literature and regulatory documents.
  • Compilation of genotoxicity assay data (e.g., Ames test, chromosomal aberration assays).
  • Compilation of carcinogenicity assay data from rodent studies.

Main Results:

  • Out of 70 examined antihistamines, 29 (41.4%) had available genotoxicity and/or carcinogenicity data.
  • 12 drugs tested positive in genotoxicity assays, six in carcinogenicity assays, and four in both.
  • Only 12 (17.1%) of the drugs met all current data requirements, with many developed before stringent regulations.

Conclusions:

  • A substantial number of marketed antihistamines lack comprehensive genotoxicity and carcinogenicity data.
  • Positive findings in safety assays were observed for several drugs, warranting further investigation.
  • The review underscores the need for updated safety assessments, especially for older medications.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Physical Properties of Amines01:26

Physical Properties of Amines

Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...